HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 286/1/E116    most recent 00331.2003v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (41) Citing Articles via Google Scholar Google Scholar Articles by Diani, A. R. Articles by Khan, M. Search for Related Content PubMed PubMed Citation Articles by Diani, A. R. Articles by Khan, M.

Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes

A. R. Diani,¹ Geri Sawada,¹ Beatrice Wyse,^1, F. T. Murray,¹ and Mehmood Khan²

¹Pharmaceutical Research and Development, The Upjohn Company, Kalamazoo, Michigan 49007; and ²Takeda Pharmaceuticals North America, Inc., Lincolnshire, Illinois 60069

Submitted 18 July 2003 ; accepted in final form 29 September 2003

Thiazolidinediones may slow the progression of type 2 diabetes by preserving pancreatic -cells. The effects of pioglitazone (PIO) on structure and function of -cells in KKA(y), C57BL/6J ob/ob, and C57BL/KsJ db/db mice (genetic models of type 2 diabetes) were examined. ob/ob (n = 7) and db/db (n = 9) mice were randomly assigned to 50-125 mg·kg body wt^-1·day^-1 of PIO in chow beginning at 6-10 wk of age. Control ob/ob (n = 7) and db/db mice (n = 9) were fed chow without PIO. KKA(y) mice (n = 15) were fed PIO daily at doses of 62-144 mg·kg body wt^-1·day^-1. Control KKA(y) mice (n = 10) received chow without PIO. Treatment continued until euthanasia at 14-26 wk of age. Blood was collected at baseline (before treatment) and just before euthanasia and was analyzed for glucose, glycosylated hemoglobin, and plasma insulin. Some of the splenic pancreas of each animal was resected and partially sectioned for light or electron microscopy. The remainder of the pancreas was assayed for insulin content. Compared with baseline and control groups, PIO treatment significantly reduced blood glucose and glycosylated hemoglobin levels. Plasma insulin levels decreased significantly in ob/ob mice treated with PIO. All groups treated with PIO exhibited significantly greater -cell granulation, evidence of reduced -cell stress, and 1.5- to 15-fold higher levels of pancreatic insulin. The data from these studies suggest that comparable effects would be expected to slow the progression of type 2 diabetes, either delaying or possibly preventing progression to an insulin-dependent state.

-cells; animal models; thiazolidinediones

This article has been cited by other articles:

				S. Cernea, R. Buzzetti, and P. Pozzilli {beta}-Cell Protection and Therapy for Latent Autoimmune Diabetes in Adults Diabetes Care, November 1, 2009; 32(suppl_2): S246 - S252. [Full Text] [PDF]

				A. Alberti, P. Karamessinis, M. Peroulis, K. Kypreou, P. Kavvadas, S. Pagakis, P. K. Politis, and A. Charonis ERp46 is reduced by high glucose and regulates insulin content in pancreatic {beta}-cells Am J Physiol Endocrinol Metab, September 1, 2009; 297(3): E812 - E821. [Abstract] [Full Text] [PDF]

				C. Evans-Molina, R. D. Robbins, T. Kono, S. A. Tersey, G. L. Vestermark, C. S. Nunemaker, J. C. Garmey, T. G. Deering, S. R. Keller, B. Maier, et al. Peroxisome Proliferator-Activated Receptor {gamma} Activation Restores Islet Function in Diabetic Mice through Reduction of Endoplasmic Reticulum Stress and Maintenance of Euchromatin Structure Mol. Cell. Biol., April 15, 2009; 29(8): 2053 - 2067. [Abstract] [Full Text] [PDF]

				A. CHATZIGEORGIOU, A. HALAPAS, K. KALAFATAKIS, and E. KAMPER The Use of Animal Models in the Study of Diabetes Mellitus In Vivo, March 1, 2009; 23(2): 245 - 258. [Abstract] [Full Text] [PDF]

				D. K. McGuire and S. E. Inzucchi New Drugs for the Treatment of Diabetes Mellitus: Part I: Thiazolidinediones and Their Evolving Cardiovascular Implications Circulation, January 22, 2008; 117(3): 440 - 449. [Full Text] [PDF]

				C. D. Lauster, T. P. McKaveney, and S. V. Muench Vildagliptin: A novel oral therapy for type 2 diabetes mellitus Am. J. Health Syst. Pharm., June 15, 2007; 64(12): 1265 - 1273. [Abstract] [Full Text] [PDF]

				A. Gastaldelli, E. Ferrannini, Y. Miyazaki, M. Matsuda, A. Mari, and R. A. DeFronzo Thiazolidinediones improve beta-cell function in type 2 diabetic patients Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E871 - E883. [Abstract] [Full Text] [PDF]

				F. Homo-Delarche, S. Calderari, J.-C. Irminger, M.-N. Gangnerau, J. Coulaud, K. Rickenbach, M. Dolz, P. Halban, B. Portha, and P. Serradas Islet Inflammation and Fibrosis in a Spontaneous Model of Type 2 Diabetes, the GK Rat Diabetes, June 1, 2006; 55(6): 1625 - 1633. [Abstract] [Full Text] [PDF]

				R. L. Hull, Z.-P. Shen, M. R. Watts, K. Kodama, D. B. Carr, K. M. Utzschneider, S. Zraika, F. Wang, and S. E. Kahn Long-Term Treatment With Rosiglitazone and Metformin Reduces the Extent of, but Does Not Prevent, Islet Amyloid Deposition in Mice Expressing the Gene for Human Islet Amyloid Polypeptide Diabetes, July 1, 2005; 54(7): 2235 - 2244. [Abstract] [Full Text] [PDF]

				F. Kawasaki, M. Matsuda, Y. Kanda, H. Inoue, and K. Kaku Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice Am J Physiol Endocrinol Metab, March 1, 2005; 288(3): E510 - E518. [Abstract] [Full Text] [PDF]